Ono Pharmaceutical

Overview

Compare with another stock.

• Ticker4528 on Tokyo Stock Exchange¹
• Industrypharmaceutical industry¹
• HeadquartersChūō-ku¹
• Websitewww.ono.co.jp
• Legal formkabushiki gaisha¹

See how the biggest companies compare on our leaderboards

Ono Pharmaceutical Co., Ltd. (小野薬品工業株式会社, Ono Yakuhin Kōgyō Kabushiki-gaisha) is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.²

Corporate structure

Ono Pharmaceutical sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Subsidiaries and ownership

Subsidiaries

• Ono Pharmaceutical (United Kingdom)

From Wikidata.¹

Timeline

1. Jul 4, 1947Founded Founded¹

Calendar

Drug trials and FDA: coming up

1. Dec 31, 2026Phase 2 trial readout expected Phase 2 trial of ONO-2020 in Agitation Associated With Alzheimer's Disease Dementia: primary completion expected Dec 31, 2026 (ClinicalTrials.gov NCT06803823).⁴
2. Jan 31, 2027Phase 3 trial readout expected Phase 3 trial of Cenobamate in Epilepsy, Generalized: primary completion expected Jan 31, 2027 (ClinicalTrials.gov NCT06579573).⁵
3. Jan 31, 2027Phase 2 trial readout expected Phase 2 trial of Cenobamate in Epilepsies, Partial: primary completion expected Jan 31, 2027 (ClinicalTrials.gov NCT06590896).⁶
4. Mar 31, 2027Phase 1/2 trial readout expected Phase 1/2 trial of E7389-LF and Nivolumab in Solid Neoplasms, run by Eisai Co., Ltd.: primary completion expected Mar 31, 2027 (ClinicalTrials.gov NCT04078295).⁷
5. Sep 30, 2027Phase 3 trial readout expected Phase 3 trial of ONO-4059 in Pemphigus: primary completion expected Sep 30, 2027 (ClinicalTrials.gov NCT06696716).⁸

Drug trials and FDA: recently

1. May 27, 2026Phase 3 trial completed Phase 3 trial of Nivolumab in Hepatocellular Carcinoma, run by Bristol-Myers Squibb: primary completion May 27, 2026, no results posted yet (ClinicalTrials.gov NCT03383458).⁹
2. Feb 16, 2026Phase 3 trial completed Phase 3 trial of Nivolumab, Gemcitabine and others in Urinary Bladder Neoplasms, run by Bristol-Myers Squibb: primary completion Feb 16, 2026, no results posted yet (ClinicalTrials.gov NCT03661320).¹⁰
3. Mar 1, 2025Phase 3 trial completed Phase 3 trial of Encorafenib, Cetuximab and others in Neoplasms, run by Pfizer: primary completion Mar 1, 2025, results posted Jun 11, 2026 (ClinicalTrials.gov NCT04607421).¹¹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Links

• Websitewww.ono.co.jp¹
• WikipediaOno Pharmaceutical
• More imagesWikimedia Commons
• WikidataQ11464265